Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890416 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 526
- Enrollment target
NCT06890416 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 526 participants.
The verdict
NCT06890416, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 526 participants
- Enrollment target
Study Summary
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Interventions
- BIOLOGICAL RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
- BIOLOGICAL HZ/su VACCINE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2025-04-04 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06890416
The ClinicalTrials.gov registry entry for NCT06890416 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE is the first listed.
NCT06890416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06890416 about?
NCT06890416 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults". This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
What is the current status of trial NCT06890416?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 526 participants. The study started on 2025-04-04. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT06890416?
The interventions under investigation include: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (BIOLOGICAL), HZ/su VACCINE (BIOLOGICAL).
Who is sponsoring clinical trial NCT06890416?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.